IGM Biosciences (IGMS) Stifel 2024 Immunology and Inflammation Virtual Summit summary

Platform and program overview

• T-cell engager platform is advancing in autoimmune diseases, with two programs in or entering clinical trials and more in development.

• Safety and efficacy data from oncology support potential in autoimmune indications.

Clinical trial progress and enrollment

• Enrollment is progressing well in SLE and lupus studies, despite a competitive environment; both have global reach.

• First two cohorts in RA and first cohort in lupus have cleared safety reviews.

• Focus on severe disease patients has led to some being screened out, but investigator and patient interest remains high.

• Myositis study, though smaller, aims to provide valuable translational data to complement RA and lupus datasets.

Data disclosure plans and endpoints

• Initial data disclosure planned for late 2024 or early 2025, requiring several cohorts with at least three months of follow-up.

• Key data points will include B-cell depletion depth/duration, autoantibody impact, clinical outcomes, and B-cell phenotype shifts.

• Safety will be a major focus, with potential for indication-specific data variability.